Business Context and Reporting Period
This Form 8-K was filed by Pacific Biosciences of California, Inc. on July 31, 2018, reporting an event that occurred on July 26, 2018. The filing addresses a specific compensatory arrangement for a senior executive and board member.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is a specific cash bonus award of $170,000.
Material Changes
There are no material changes to financial performance or operations reported in this document. The filing solely discloses a new compensatory arrangement approved by the Compensation Committee.
Management Commentary and Unusual Items
The Compensation Committee of the Board of Directors approved a cash bonus of $170,000 for Ms. Kathy Ordoñez. This award is compensation for her work as Chief Commercial Officer and Executive Vice President. Ms. Ordoñez is also a member of the Board of Directors.
Investor Verification Checklist
- Verify the total compensation package for Ms. Kathy Ordoñez beyond this specific bonus.
- Confirm the impact of this bonus on the company's total executive compensation expenses for the fiscal period.
- Review the company's most recent 10-Q or 10-K for comprehensive financial performance data not included in this 8-K.